Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018635 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT07018635 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 63 participants.
The verdict
NCT07018635, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG INCB161734
- DRUG Esomeprazole
- DRUG Famotidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2025-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07018635
The ClinicalTrials.gov registry entry for NCT07018635 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Rifampin is the first listed.
NCT07018635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07018635 about?
NCT07018635 is a clinical study titled "A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants". This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.
What is the current status of trial NCT07018635?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2025-07-16. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT07018635?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), INCB161734 (DRUG), Esomeprazole (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT07018635?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.